Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Somebody is having a great momentum play on this...3rd time in a week it reaches 0.007+ and we can't hold onto the gains. We are probably going to dip down to 0.0044 (support level) today or tomorrow and see another bounce back upto the 0.007-0.008 levels. People are swing trading this stock and not holding for possible news and potential big gains.
Glad see you back RuLiquid
Love It. Go POSC! Now can COV step upto the plate for the winning score
Thanks for the update. Holding strong
SSPT RegSho List Volume for June upto 6/21
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51547929
It's going to bounce, the question is just when and how high
I heard that the MM's have to balance the books at the end of everymonth and all loaned shares (shorts) have to be covered by then if it is above a certain % and nr of days. Not sure how true this is. I will contact a buddy of mine. He is MM....
Is our day finally nearing?
Now would be a good time for the BIG PR
SSPT RegSho List Volume for June:
20100621|SSPT|116622359|306569085|O
20100618|SSPT|130254739|428061626|O
20100617|SSPT|135121568|410032002|O
20100616|SSPT|126760133|223688728|O
20100615|SSPT|110497499|155893800|O
20100614|SSPT|12766546|30937623|O
20100611|SSPT|1425000|7673900|O
20100610|SSTP|103500|493700|O
20100609|SSPT|2108050|10423782|O
20100608|SSPT|4835553|27064754|O
20100607|SSPT|12634242|34675327|O
20100604|SSPT|50029853|135307785|O
20100602|SSPT|54399701|135339832|o
20100601|SSPT|64662450|171963943|O
SSPT shorted 822221193shares so far in June...This is one massive squeeze in the making and with any news this is GOING to HIGHER. The question is just when not if
From GuestMetrics Website SSPT list of clients. There is two pages so scroll to the second page to see all the customers. Quite a list:
http://www.guestmetrics.com/clients.html
Yes you are..Fun and games in the morning...expect the same trading day tomorrow unless AH or AM news blows it away..Volume is surely there
Nice Uptick there at the close..Watch for A/H news or AM news..She is going to fly when this happens
More to come..We have about 100Mil shares shorted so far..The MM's is going cover here soon..
132Mil buy v 125mil sell trades so far...Watch for EOD close.
Buy orders out numbers sell orders so far today...
All of the penny stocks is lethargic this morning...Expect things to wake up during the lunch hour...Must be Summer Holidays setting in/
Well POSC is well position to exceed their sales targets for 2010.
Time to move back up. Nice basin formed..Lets do a cup
I call 0.13+ close for today
Thanks. This is going back to 0.03.
CuspID changes is triggered by a corporate action such as a:
Change in company name;
Reorganization;
Merger;
Forward stock split, when payable upon surrender of certificates;
Reverse stock split; or
Emergence from bankruptcy.
We know that they have been working dilligently to retire shares so the only LOGIC explanation for a CUSPID would be a reorganization, name change or merger.
I hope you are right...
Also want to add that Covidien has FDA approval int he US for the Generic Kit for the Preparation of Technetium Tc 99m Sestamibi Injection
I just bought 4Mill shares @0015 and it showed as a sell on level2. So the MM's are shorting the hell out of this stock right now. I just don't get it!
There is NOTHING you can tell me about this stock. I'm in this industry and on the forefront of it. I know about ROONEY &CO and it doesn't phase me because I can look past that at the IP and potential of this company. Partnering news with multiple industry leaders is going to confirm what POSC longs already know: Solid company with a HUGE potential for growth over the next 18months and then a buyout.
And that is how the story is going to UNFOLD and END. EOM.
POSC Put on RADAR for tomorrow...BIG News expected that is going to ROCK the PPS up
POSC ALERT>>>Put on the radar for more tomorrow..news expexted around midday that is going to send the PPS to the Moon....
POSC ALERT>>Great news out today>>>Up 12% with even bigger partnering news expected tomorrow midday. Watch this run tomorrow. Keep this one on your radars for take off. Party is starting....
SSPT ALERT>>>Huge news out on partnering with AMEX today>>Up 108% with a big gap and run expected tomorrow. Target 0.015..Multi bagger
Tomorrow we are going to ROCK...More NEWS expected. It's all going to come together over the next week....We are going to go KABOOM
Buys 186Mill Sells:168Mill as of 3.23pm est
Can somebody please ban this individual from this board? If you are not a POSC investor then shut up and get OFF our board.
More DD part 2 from today's PR:
Positron has a number of patents and patents pending. Most recently has received a patent on its Tech-Assist™, FDG injection shielding device.
Some POSC current R&D projects"
Positron Corporation Acquires Exclusive License to Coronary Disease Reversal and Prevention Practice Management Program from the University of Texas. HOUSTON Tuesday, 1 July 2008 -- Positron Corporation (OTC: POSC) (the "Company") announced today that it has acquired an exclusive license to a coronary disease reversal and prevention practice management program created by K. Lance Gould, M.D. and the University of Texas Health Science Center at Houston.
"We are grateful to the University of Texas Health Science Center at Houston and Dr. Gould for selecting Positron Corporation as the exclusive licensee of their heart disease management product", stated Joe Oliverio, President of Positron. Oliverio also stated, "the market is void of such a product and will position Positron to be able to offer a total cardiac solution to customers reaching well beyond the sale to physicians."
"The Weatherhead P.E.T. Center of the University of Texas Health Science Center at Houston is unique for having the most advanced myocardial perfusion imaging in the world using positron emission tomography (P.E.T.) integrated with intense lifestyle and pharmacologic treatment proven to reduce invasive procedures and coronary events compared to conventional cardiovascular practices", stated K. Lance Gould, M.D., holder of the Martin Bucksbaum Distinguished University Chair, professor of Cardiovascular Medicine and executive director of the Weatherhead P.E.T. Center for Preventing and Reversing Atherosclerosis, University of Texas Medical School at Houston.
Dr. Gould went on to also state, "This first program for the optimal one-stop combination of diagnostic assessment, vigorous pharmacologic and lifestyle management is PET technology driven but incorporates the humanity and knowledge of the best preventive and clinical medicine. It identifies the earliest stages of coronary disease and before symptoms develop. It also determines when invasive procedures are unnecessary or needed for the most advanced complex coronary heart disease."
"Positron Corporation has recognized the power of this approach for improving cardiovascular care. The University of Texas Health Science Center at Houston- Positron agreement highlights the commitment of the University and Positron for translating the highest quality cardiovascular medicine and research of a renowned academic center into widespread application of community practice."
As part of the program Positron Corporation and Disease Management, LLC has a Signed Agreement to Co-Develop a Coronary Artery Disease Reversal and Prevention Software Program and Total Disease Management Solution.
The product will include a heart disease pre-test risk calculator, a Coronary Disease Reversal and Prevention practice management program, a web-based, patient centric, disease reversal and life style modification program, an interpreting and referring physician portal, as well as a cost efficacy and patient outcomes tracker.
Positron Corporation's President Joseph G. Oliverio stated, "The development of our heart disease management solution will help us reach beyond our current molecular imaging targeted business to offer a product to payers, self insured corporations, multi-specialty groups, cardiology cardiology
Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. groups, hospitals and finally direct to the consumer."
Oliverio also adds that "This is an important step in the growth of our business and the impact on the industry that Positron has been positioning for over the past 2 years. The product introduction will address a first-to-market opportunity in the Coronary Disease Reversal and Prevention sector which strengthens Positron's core products that are focused on providing accurate, cost effective imaging and disease management solutions. One of our many goals is to offer even the smallest community hospitals the same level of quality of our most experienced users."
Total POSC Investment to date: $4Mill. 5 year study for completion in Summer 2013.
More DD part 1 from today's PR"
1.'Radiopharmaceuticals, Sestimibi and Rubidium, are now available as a generic pharmaceutical and are set to become commercially available with a number of pharma companies. Lower cost and increased suppliers will help grow our segment of the industry. Positron is working with the largest companies in this field.
- Rubidium (brand name CardioGen 82R). The only generator-based Positron Emission Tomography agent reimbursed for the evaluation of coronary artery disease. Only supplied by Bracco Diagnostics to the industry. On September 23 2008, Bracco Diagnostics Inc., the US-based subsidiary of Bracco Imaging SpA and part of the Bracco Group, and Lantheus Medical Imaging, Inc., both worldwide leaders in diagnostic imaging, announced today that the companies have entered into an agreement for Lantheus to co-promote Bracco’s CardioGen-82® (Rubidium Rb 82 Generator), a myocardial perfusion Positron Emission Tomography (PET) imaging agent. CardioGen-82 is the only generator-based PET perfusion agent approved by the U.S. Food and Drug Administration (FDA) and reimbursed for the evaluation of coronary artery disease (CAD).
- Sestimibi (brand name Cardio Lite). Cardio Lite is manufactured by Lantheus. Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien’s generic product is fully substitutable for Cardiolite(R), a myocardial perfusion imaging agent used for detecting coronary artery disease. Covidien got approval for the generic kit in July 2008 and has approval for sale and distribution in the the U.K., Denmark, Germany and Puerto Rico. A ANDS in Canada is pending. Pharmalucence also got approval for the generic version in Jyly 2009.
Something coming...the start of the express train
Thank you. Just called and they referred me to Positron.
Thanks
Crammerfoot...Trading agent for POSC..Want to confirm the share count....See if any dilution has happened since May...
Anybody know the TA phone nr?
NDYN>>>Creeping up slowly>>22% up today. Bottom reversal play with muli million $$$ contract news expected later this week